Concordance Between Trial Efficacy and Real-World Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis.
SGLT2 inhibitors show real-world mortality benefits for heart failure that align with clinical trial results, suggesting genuine clinical value.
We assessed whether their effectiveness in routine practice is concordant with trial efficacy, appraising and pooling each evidence stream separately. Real-world mortality associations with SGLT2 inhibitors in HFrEF are directionally concordant with trial efficacy, but their larger magnitude most plausibly reflects residual confounding, including co-prescription of other guideline-directed therapy.
What the study was
- Study design
- Systematic review and meta-analysis
- Population
- PubMed/MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov were searched from January 1, 2015 to July 2026 for randomized trials and comparative observational studies of SGLT2 inhibitors vs. placebo or nonuse in adults with left ventricular ejection fraction ≤40% reporting mortality or heart failure hospitalization.
- Category
- Prevention
- Maturity
- Validated
- Journal
- Cureus
Why it surfaced
Systematic review and meta-analysis with a PubMed abstract reviewed; the 8/10 score reflects conservative novelty, relevance, design-quality, and population/unmet-need assessment.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.